Medium materiality5/10
Truist raises Zymeworks price target to $35
Why it may matterVerify against the original reporting
The target increase and implied upside are moderately bullish analyst signals, subject to the uncertainty of analyst estimates.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Truist raised its ZYME price target to $35; the posted price of $28.85 is about 21% below the target.
- Truist raised its ZYME target to $35.
- The target is about 21% above the posted $28.85 price.
Key facts
- 01
Target: $35
- 02
Posted price: $28.85
- 03
Analyst firm: Truist Financial
- 04
Analyst: Gregory Renza
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.